Methotrexate lung disease
Citation, DOI, disclosures and article data
At the time the article was created Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
Methotrexate lung disease is a specific etiological type of drug-induced lung disease. It can occur due to the administration of methotrexate, which is an antimetabolite, commonly prescribed to treat rheumatoid arthritis. It is also given alone or in combination with other chemotherapeutic agents to treat a wide variety of malignancies including lung, breast, and head and neck epidermoid cancers, non-metastatic osteosarcoma, and advanced-stage non-Hodgkin lymphoma.
It is thought to occur in ~5% (range 0.3-10%) of patients treated with methotrexate 1-2.
The typical clinical symptoms include progressive shortness of breath and cough, often associated with fever 6. Hypoxemia and tachypnea are always present and crackles are frequently audible. Symptoms typically manifest within months of starting therapy). There appears to be no correlation between the development of drug toxicity and the duration of therapy or total cumulative dose) 1. Anaphylaxis and anaphylactoid reactions are reported.
There can be several manifestations of methotrexate-related lung changes:
methotrexate-induced pneumonitis: 1% of rheumatoid arthritis patients starting methotrexate 10. NSIP pattern and granuloma formation
pleural effusion / pleuritis 15 but also reported in rheumatoid arthritis in general 14
organizing pneumonia: has been associated with methotrexate use but can also occur in the setting of new diagnosis rheumatoid arthritis 13
superimposed pulmonary infection 10
Previously, methotrexate was thought to cause pulmonary fibrosis, however, more recent evidence (c. 2021) has not established a causative effect 10-12.
BAL may show an excess proportion of lymphocytes.
CT features can be variable and included diffuse parenchymal opacification, reticular opacities, and centrilobular nodules 2. An NSIP pattern is considered the most common manifestation of methotrexate-induced lung disease 1.
Treatment and prognosis
Overall prognosis would depend on the exact form of the disease. In general, the prognosis is considered good, with most patients improving despite the continuation of therapy. Patients with lung fibrosis at presentation may have worse prognosis 2.
- 1. Rossi S, Erasmus J, McAdams H, Sporn T, Goodman P. Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations. Radiographics. 2000;20(5):1245-59. doi:10.1148/radiographics.20.5.g00se081245 - Pubmed
- 2. Arakawa H, Yamasaki M, Kurihara Y, Yamada H, Nakajima Y. Methotrexate-Induced Pulmonary Injury: Serial CT Findings. J Thorac Imaging. 2003;18(4):231-6. doi:10.1097/00005382-200310000-00004 - Pubmed
- 3. Ellis S, Cleverley J, Müller N. Drug-Induced Lung Disease: High-Resolution CT Findings. AJR Am J Roentgenol. 2000;175(4):1019-24. doi:10.2214/ajr.175.4.1751019 - Pubmed
- 4. Camus P, Kudoh S, Ebina M. Interstitial Lung Disease Associated with Drug Therapy. Br J Cancer. 2004;91 Suppl 2(Suppl 2):S18-23. doi:10.1038/sj.bjc.6602063 - Pubmed
- 5. Cannon G. Methotrexate Pulmonary Toxicity. Rheum Dis Clin North Am. 1997;23(4):917-37. doi:10.1016/s0889-857x(05)70366-5 - Pubmed
- 6. Imokawa S, Colby T, Leslie K, Helmers R. Methotrexate Pneumonitis: Review of the Literature and Histopathological Findings in Nine Patients. Eur Respir J. 2000;15(2):373-81. doi:10.1034/j.1399-3003.2000.15b25.x - Pubmed
- 7. Chhabra P, Law A, Suri V, Malhotra P, Varma S. Methotrexate Induced Lung Injury in a Patient with Primary CNS Lymphoma: A Case Report. Mediterr J Hematol Infect Dis. 2012;4(1):e2012020. doi:10.4084/MJHID.2012.020 - Pubmed
- 8. Hargreaves M, Mowat A, Benson M. Acute Pneumonitis Associated with Low Dose Methotrexate Treatment for Rheumatoid Arthritis: Report of Five Cases and Review of Published Reports. Thorax. 1992;47(8):628-33. doi:10.1136/thx.47.8.628 - Pubmed
- 9. Everts C, Westcott J, Bragg D. Methotrexate Therapy and Pulmonary Disease. Radiology. 1973;107(3):539-43. doi:10.1148/107.3.539 - Pubmed
- 10. Dawson J, Quah E, Earnshaw B, Amoasii C, Mudawi T, Spencer L. Does Methotrexate Cause Progressive Fibrotic Interstitial Lung Disease? A Systematic Review. Rheumatol Int. 2021;41(6):1055-64. doi:10.1007/s00296-020-04773-4 - Pubmed
- 11. Sweis J, Sweis N, Alnaimat F et al. Immune-Mediated Lung Diseases: A Narrative Review. Front Med (Lausanne). 2023;10:1160755. doi:10.3389/fmed.2023.1160755 - Pubmed
- 12. Dinache G, Popescu C, Mogoșan C, Enache L, Agache M, Codreanu C. Lung Damage in Rheumatoid Arthritis-A Retrospective Study. Int J Mol Sci. 2022;24(1):28. doi:10.3390/ijms24010028 - Pubmed
- 13. Mori S, Koga Y, Sugimoto M. Organizing Pneumonia in Rheumatoid Arthritis Patients: A Case-Based Review. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):69-80. doi:10.4137/CCRPM.S23327 - Pubmed
- 14. Fujita S, Mukai T, Akagi T, Morita Y. Treatment of Refractory Rheumatoid Pleural Effusion with Abatacept. BMJ Case Rep. 2018;2018:bcr-2017-224034. doi:10.1136/bcr-2017-224034 - Pubmed
- 15. Methotrexate-Induced Pleurisy. J Am Acad Dermatol. 2013;68(4):AB140. doi:10.1016/j.jaad.2012.12.579
- 16. Iwami E, Ito F, Sasahara K et al. Pulmonary Intravascular Large B-Cell Lymphoma in a Patient Administered Methotrexate for Rheumatoid Arthritis. Intern Med. 2020;59(3):429-33. doi:10.2169/internalmedicine.3216-19 - Pubmed